AR and benign prostatic hyperplasia: EGF can also reduce the expression of androgen receptor (AR) in differentiated mouse vas deferens epithelial cells, inhibit the signal transduction of androgen signaling, and promote the reentry of differentiated cells into the cell cycle.[59] These results suggest that EGF and its interaction with the androgen signaling pathway are important targets for the treatment of BPH.